436 related articles for article (PubMed ID: 28830945)
1. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.
Negri CE; Johnson A; McEntee L; Box H; Whalley S; Schwartz JA; Ramos-Martín V; Livermore J; Kolamunnage-Dona R; Colombo AL; Hope WW
J Infect Dis; 2018 Mar; 217(7):1118-1127. PubMed ID: 28968675
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.
du Pré S; Beckmann N; Almeida MC; Sibley GEM; Law D; Brand AC; Birch M; Read ND; Oliver JD
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891595
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Olorofim (F901318) against
Seyedmousavi S; Chang YC; Law D; Birch M; Rex JH; Kwon-Chung KJ
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885903
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
8. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.
Lackner M; Birch M; Naschberger V; Grässle D; Beckmann N; Warn P; Gould J; Law D; Lass-Flörl C; Binder U
J Antimicrob Chemother; 2018 Nov; 73(11):3068-3073. PubMed ID: 30351438
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
[TBL] [Abstract][Full Text] [Related]
12. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5438-47. PubMed ID: 23959322
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.
Howard SJ; Lestner JM; Sharp A; Gregson L; Goodwin J; Slater J; Majithiya JB; Warn PA; Hope WW
J Infect Dis; 2011 May; 203(9):1324-32. PubMed ID: 21357943
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.
Gastine S; Hope W; Hempel G; Petraitiene R; Petraitis V; Mickiene D; Bacher J; Walsh TJ; Groll AH
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168606
[No Abstract] [Full Text] [Related]
15. The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis.
Garvey EP; Sharp AD; Warn PA; Yates CM; Atari M; Thomas S; Schotzinger RJ
Med Mycol; 2020 Jun; 58(4):505-513. PubMed ID: 32476008
[TBL] [Abstract][Full Text] [Related]
16. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6284-9. PubMed ID: 24100500
[TBL] [Abstract][Full Text] [Related]
18. APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
Zhao M; Lepak AJ; Marchillo K; Vanhecker J; Sanchez H; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670426
[TBL] [Abstract][Full Text] [Related]
19. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
